司来吉兰对年轻志愿者中左旋多巴外周药代动力学的影响。
The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers.
作者信息
Roberts J, Waller D G, O'Shea N, Macklin B S, Renwick A G
机构信息
Clinical Pharmacology Group, University of Southampton, UK.
出版信息
Br J Clin Pharmacol. 1995 Oct;40(4):404-6. doi: 10.1111/j.1365-2125.1995.tb04564.x.
Abstract
The plasma pharmacokinetics of levodopa were studied in eight healthy young subjects following an i.v. infusion of 50 mg over 5 min. Subjects were studied on two occasions in random order following treatment with carbidopa; on one occasion they were pretreated with selegiline (four doses of 10 mg over the preceding 3 days) and on the other with a placebo. The mean plasma concentration-time curves on each occasion were essentially superimposable and there were no significant differences in any calculated pharmacokinetic parameter. Selegiline does not significantly alter the distribution or elimination of levodopa from plasma.
摘要
在8名健康年轻受试者中，静脉输注50毫克左旋多巴，历时5分钟，研究其血浆药代动力学。受试者在接受卡比多巴治疗后分两次随机接受研究；一次是在接受司来吉兰预处理（在前3天服用4剂，每剂10毫克）后，另一次是在接受安慰剂治疗后。每次的平均血浆浓度-时间曲线基本可叠加，任何计算得出的药代动力学参数均无显著差异。司来吉兰不会显著改变左旋多巴在血浆中的分布或消除。
相似文献
1
The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers.司来吉兰对年轻志愿者中左旋多巴外周药代动力学的影响。
Br J Clin Pharmacol. 1995 Oct;40(4):404-6. doi: 10.1111/j.1365-2125.1995.tb04564.x.
2
Intravenous levodopa administration in humans based on a two-compartment kinetic model.
J Neurosci Methods. 2007 Jan 30;159(2):300-7. doi: 10.1016/j.jneumeth.2006.07.010. Epub 2006 Aug 24.
3
The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers.苯海索与左旋多巴联合给药对年轻志愿者口服左旋多巴外周药代动力学的影响。
Br J Clin Pharmacol. 1996 Apr;41(4):331-7. doi: 10.1046/j.1365-2125.1996.32311.x.
4
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.盐酸多奈哌齐与左旋多巴/卡比多巴联合用于帕金森病患者：多次口服给药后药代动力学变化及安全性评估
Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x.
5
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.左旋多巴-卡比多巴肠凝胶的药代动力学：变异性低于口服左旋多巴-卡比多巴。
J Parkinsons Dis. 2017;7(2):275-278. doi: 10.3233/JPD-161042.
6
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.左旋多巴/卡比多巴/恩他卡朋不同给药方案对血浆左旋多巴浓度的影响。
Eur J Clin Pharmacol. 2012 Mar;68(3):281-9. doi: 10.1007/s00228-011-1121-5. Epub 2011 Sep 17.
7
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.息宁控释片的药代动力学和生物利用度：人体研究综述
Neurology. 1989 Nov;39(11 Suppl 2):25-38.
8
A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.十二指肠左旋多巴输注的药代动力学-药效学模型。
Clin Neuropharmacol. 2011 Mar-Apr;34(2):61-5. doi: 10.1097/WNF.0b013e31820b570a.
9
Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.尼可占替诺和盐酸司来吉兰控释片在健康人体的药代动力学-药效学相互作用：一项单中心、Ⅰ期、双盲、随机、安慰剂对照、四交叉研究。
Clin Ther. 2009 Oct;31(10):2258-71. doi: 10.1016/j.clinthera.2009.10.019.
10
Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease.帕金森病患者左旋多巴药代动力学的昼夜节律性。
Clin Neuropharmacol. 2010 Jul;33(4):181-5. doi: 10.1097/WNF.0b013e3181e70f7a.
引用本文的文献
1
Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.抗帕金森病药物：临床显著的药物相互作用和不良反应及其管理。
CNS Drugs. 1998 Apr;9(4):291-310. doi: 10.2165/00023210-199809040-00005.
2
The Human Experience with Intravenous Levodopa.静脉注射左旋多巴的人体试验经历
Front Pharmacol. 2016 Jan 6;6:307. doi: 10.3389/fphar.2015.00307. eCollection 2015.
3
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.帕金森病治疗中的药代动力学优化：最新进展
Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001.
本文引用的文献
1
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.恩他卡朋抑制儿茶酚-O-甲基转移酶对健康志愿者左旋多巴药代动力学及代谢的影响。
Clin Neuropharmacol. 1993 Apr;16(2):145-56. doi: 10.1097/00002826-199304000-00007.
2
Effects of selegiline dosing on motor fluctuations in Parkinson's disease.
Clin Neuropharmacol. 1993 Feb;16(1):83-7. doi: 10.1097/00002826-199302000-00010.
3
Selegiline in de novo parkinsonian patients: the Finnish study.司来吉兰用于初发帕金森病患者：芬兰的研究。
Mov Disord. 1993;8 Suppl 1:S41-4. doi: 10.1002/mds.870080509.
4
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.儿茶酚-O-甲基转移酶（COMT）抑制剂恩他卡朋对帕金森病患者临床残疾及左旋多巴代谢的影响。
Neurology. 1994 Jan;44(1):77-80. doi: 10.1212/wnl.44.1.77.
5
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
Intern Med. 1994 Sep;33(9):517-24. doi: 10.2169/internalmedicine.33.517.
6
Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.
Neurology. 1981 Oct;31(10):1288-94. doi: 10.1212/wnl.31.10.1288.
7
Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.左旋多巴和司来吉兰给药后人体脑脊液中多巴胺和3,4-二羟基苯乙酸（DOPAC）水平的变化。
J Neural Transm. 1983;58(3-4):299-304. doi: 10.1007/BF01252815.
8
Variability of L-dopa absorption in man.
Aust N Z J Med. 1974 Apr;4(2):138-43. doi: 10.1111/j.1445-5994.1974.tb03162.x.
9
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.开关现象：与左旋多巴药代动力学和药效学的关系。
Ann Neurol. 1987 Oct;22(4):535-40. doi: 10.1002/ana.410220415.
10
Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.不同单胺氧化酶抑制剂对大鼠脑内左旋多巴代谢的影响。
Biochem Pharmacol. 1987 May 15;36(10):1731-5. doi: 10.1016/0006-2952(87)90060-8.
Zotero 插件